GW Pharmaceuticals PLC shares rose more than 4% in the extended session Monday after the company reported positive phase-three trial results and narrowing losses. The company reported first-quarter net losses of $50.1 million, or 14 cents a share, compared with losses of $69.5 million, or 20 cents a share, in the year-ago period. Revenue rose to $39.2 million from $3.04 million in the year-ago period. The company also reported positive results from a phase-three trial involving a drug with cannabidiol, or CBD. GW stock has gained 28% in the past year, with the S&P 500 index rising 11%.